How often do you stop and think about your immune system? If you live with one of the more than 80 immune-mediated diseases, you probably think about it more than most.
Immune-mediated diseases are chronic and can have a significant impact on a person’s quality of life due to potential physical, emotional and psychological burdens. Today, four to five percent of people in the world live with an immune-mediated disease.
Even with the current treatment options that are available to treat many immune-mediated diseases, there is still a significant unmet need for people living with these diseases. That is why we aspire to deliver innovative medicines that enable breakthrough outcomes to address the unresolved impact of immune-mediated diseases.
Lilly has been able to provide immunology treatments to more than 1.5 million people around the world, but there are many more in need. That’s what motivates us to continue to find the next generation of treatments.
Understanding the Impact of Immune-mediated Diseases
Your immune system is a complex network of cells, tissues and organs that help fight infections and disease. It’s an incredibly important job. When that system isn’t working properly, it impacts the way the body responds to these threats, and this systemic dysfunction is what causes immune-mediated diseases.
When you live with an immune-mediated disease, you can experience joint pain, muscle weakness, skin disorders and fatigue. Additionally, immune-mediated diseases can affect almost any organ system in the body. But these diseases can also have a broader impact—causing emotional, psychological, and even financial challenges.
In the more severe cases, these diseases can also cause serious disability and reduced life expectancy. Some immune-mediated diseases may impact certain communities more often, like women and people of color.
For far too many, the unresolved impact of living with an immune-mediated disease often leads to a life with unwanted compromise. People deserve effective, safe and accessible treatments that allow them to live with less compromise. That’s our focus: provide more options that allow people suffering from immune-mediated diseases to live better lives.
Creating Inclusivity in Clinical Trials
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease characterized by intense itching, dry skin and inflammation on any part of the body. For people of color, AD may present with unique symptoms, and in previous clinical trials, there has been limited representation. Learn more on this episode of The Elixir Factor about the impact of AD – particularly in people of color – and the steps Lilly is taking to generate new disease information to aid investigators and clinicians in providing diagnoses and treatment options for all skin tones.
Setting New Expectations in Immunology
People living with immune-related diseases can’t afford to settle—their quality of life depends on new discoveries in this space. The new ideas of today become the standard of care tomorrow.
That’s what pushes us to keep searching. Our current Immunology medicines, and those in the pipeline, have the potential to impact a broad range of people living with diseases that cause issues with skin, gastrointestinal problems, and pain.
We’re not comfortable with the status quo. There are too many people suffering from a variety of symptoms caused by immune-related diseases. That’s what keeps us expanding our research and development, investing in next-generation medicines, and exploring new innovations.
We embrace a fundamental challenge: Redefine what’s possible for people living with immune-related diseases.
Understanding the Impact of UC
Seven million people globally are living with inflammatory bowel diseases (IBD), a term for the chronic conditions that encompass both ulcerative colitis and Crohn’s disease. These diseases can affect how people work, travel and spend time with family and friends, and can be difficult to talk about with loved ones and health care providers. Listen to this episode of The Elixir Factor, where guests discuss how Lilly’s global cross-functional CONFIDE survey helped us better understand the impact of these diseases.